Natura &Co's Profit Beat Fails to Close the Expectation Gap—Avon Relaunch Now the Make-or-Break Catalyst

The market's verdict on Natura &Co's fourth quarter was a stark lesson in expectation arbitrage. The company delivered a clear beat on its core profitability target, yet the stock punished the news. The tension lies in what was priced in versus what actually happened.

On paper, the profit story was strong. For the full year 2025, the company achieved a recurring EBITDA margin of 14.6%, hitting its annual target and marking a 130-basis-point improvement. More importantly, the final quarter itself showed a powerful acceleration, with the recurring EBITDA margin in Latin America reaching 16.1%. This was the kind of execution the market had been waiting for after years of integration costs.

Yet the stock reacted with a 2.5% drop on the day, extending a prior 30% fall. This is the classic "sell the news" dynamic. The beat was real, but it appears the market had priced in even better news. The real disappointment was in the drivers behind the numbers and the forward view. JPMorgan's downgrade to 'Neutral' captures the shift in sentiment. Their reasoning points to a loss of execution trust, noting that "the earnings miss raises questions about margin improvement trends while blurring medium-to-longer term visibility." In other words, the margin beat was seen as a one-off, potentially driven by one-time efficiencies or divestments, rather than a durable new trajectory.

The bottom line is that the market had already bought the rumor of a clean, profitable turnaround. The reality, with a weak core earnings print and a guidance reset, was worse than expected. The stock's plunge shows that even a beat can be punished if it fails to close the expectation gap.

The Whisper Number vs. The Print: Brazil's Top-Line Miss

The expectation gap wasn't just about profits; it was also about growth. For Brazil, the market was likely pricing in modest top-line stability or a slight recovery. Instead, the company reported a 4.8% year-over-year decline in Brazil's top-line performance in Q4. This miss was the concrete reality that clashed with the whisper number.

The drivers were clear and pointed to ongoing operational friction. Management cited channel downsizing and lower activity among less productive consultants as the primary causes. This isn't a demand shock; it's a deliberate, if painful, restructuring. The weakness in Avon Brazil was even starker, with revenue down 11.5% due to a light innovation pipeline. In other words, the market was expecting a bounce-back, but the company was still in the midst of a painful reset.

This top-line stumble overshadowed the strong profitability beat. It amplified the "sell the news" dynamic because it confirmed the narrative that the turnaround is not a smooth, revenue-led recovery. The profit margin improvement, while real, now looks more like a function of cost discipline and asset sales than a fundamental revival in consumer demand. As JPMorgan noted, the "earnings miss raises questions about margin improvement trends while blurring medium-to-longer term visibility." When the core growth engine sputters, even a clean profit line can be viewed as temporary.

The bottom line is that the market had priced in a cleaner, more balanced recovery. The reality-a declining Brazil revenue base amid a costly restructuring-was worse than expected. This gap between the whisper number and the print is what drove the stock's sharp decline, turning a profit beat into a broader disappointment.

Financial Impact and Valuation Implications

The tangible outcomes from the quarter are a mixed bag, but the valuation shift tells the clearer story. On one hand, the company has successfully simplified its structure and maintained financial discipline. It ended the year with a net debt to EBITDA ratio of 1.3 times, squarely within its target range. This shows the balance sheet is stable and the capital structure reorganization is complete. On the other hand, the cash flow impact was significant, with a 732 million drag from working capital, mostly inventory-driven, which will pressure liquidity in the near term.

Management's response to the weak earnings print was a classic signal of confidence in the long-term view: a share buyback program. Following the stock's sharp drop, the company approved a program to purchase up to 52.63 million shares, or 6.2% of its free float. This move is designed to return capital and support the share price, but it also underscores the market's lack of trust. The buyback is being executed at a depressed valuation, a sign that management believes the current price doesn't reflect the underlying business strength.

The most telling indicator, however, is the reset in analyst valuation. JPMorgan's downgrade to 'Neutral' and its dramatic price target cut from 21.00 reais to 11.00 reais captures the new investment case. This isn't just a minor adjustment; it's a fundamental reset of the multiple applied to the stock. The firm cited that the earnings miss raises questions about margin trends and blurs long-term visibility. In other words, the market is now pricing in a higher risk premium for the execution uncertainty that the profit beat failed to resolve.

The bottom line is that the financial outcomes are not catastrophic, but they are insufficient to close the expectation gap. The maintained leverage and buyback program are positive steps, but they are being overshadowed by a valuation that has been reset to reflect a more cautious outlook. The stock's plunge shows that investors are demanding more than just a clean balance sheet and a promise to buy back shares; they want proof that the top-line decline is temporary and that the margin improvement is sustainable. Until then, the valuation will remain under pressure.

Catalysts and Risks: The Path to Re-rating

The path to a re-rating for Natura &Co now hinges on a few clear, near-term tests. The company has completed its structural overhaul, but the market is waiting for proof that this new, simpler entity can drive sustainable growth. The key catalyst is the relaunch of the Avon brand in Brazil and Mexico, which kicked off this March. This is the first major commercial test of the integrated model. Success here-measured by early sell-through data and a return to market share gains-could begin to shift the narrative from cost-driven profitability to a balanced, revenue-led recovery.

The primary risk, however, is the entrenched 'sell the news' dynamic. The market has already punished the stock for a weak earnings print, and it remains skeptical that the strong profitability is durable. The persistent 4.8% year-over-year decline in Brazil's top-line performance in Q4 and the ongoing integration noise in Mexico and Argentina create a backdrop where any positive news on margins gets overshadowed by concerns over the core growth engine. As JPMorgan noted, the earnings miss "raises questions about margin improvement trends while blurring medium-to-longer term visibility." This skepticism is the market's current baseline.

For investors, the monitoring framework is straightforward. Watch for two things in the coming quarters. First, inventory sell-through data from the Avon relaunch. The CEO stated they expect to "detect inventory movement within a quarter," so early signs of healthy consumer adoption are critical. Second, look for evidence that the company is regaining market share in Brazil, not just managing costs. The CEO mentioned speeding up the launch pipeline and boosting sales force incentives, but the market needs to see that translate into top-line stability.

The bottom line is that the expectation gap is wide, and closing it requires more than a clean profit line. It requires the Avon relaunch to succeed and for the market to believe that the top-line weakness is a temporary, restructuring-related dip, not a permanent shift. Until then, the stock will likely remain vulnerable to any stumble in the new commercial cycle.